---
title: "Hualan Biological Vaccine Inc. (301207.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/301207.SZ.md"
symbol: "301207.SZ"
name: "Hualan Biological Vaccine Inc."
industry: "Biotechnology"
datetime: "2026-05-21T17:30:35.718Z"
locales:
  - [en](https://longbridge.com/en/quote/301207.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301207.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301207.SZ.md)
---

# Hualan Biological Vaccine Inc. (301207.SZ)

## Company Overview

Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetically engineered biological products in China. The company’s main products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, quadrivalent influenza virus split vaccine (pediatric formulation), H1N1 influenza A virus split vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hansenula polymorpha), group A and C meningococcal polysaccharide vaccine, freeze-dried human rabies vaccine (Vero cells), and adsorbed tetanus vaccine. It also offers products under development, such as freeze-dried Group A and Group C meningococcal conjugate vaccine, adsorbed cell-free tridiphtheria-tetanus combined vaccine, freeze-dried Haemophilus influenzae type b conjugate vaccine, and recombinant zoster vaccine (CHO cells), mRNA influenza vaccines, adsorbed tetanus vaccine, and novel adjuvanted influenza vaccines.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.hualanbacterin.com](https://www.hualanbacterin.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: C (0.42)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 33 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 7.79% |  |
| Net Profit YoY | -6.11% |  |
| P/B Ratio | 2.09 |  |
| Dividend Ratio | 3.97% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 11961449374.10 |  |
| Revenue | 1202682148.07 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 3.18% | C |
| Profit Margin | 15.56% | A |
| Gross Margin | 70.92% | A |
| Revenue YoY | 7.79% | C |
| Net Profit YoY | -6.11% | C |
| Total Assets YoY | -8.11% | E |
| Net Assets YoY | -5.06% | D |
| Cash Flow Margin | 245.74% | A |
| OCF YoY | 7.79% | C |
| Turnover | 0.17 | D |
| Gearing Ratio | 16.05% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hualan Biological Vaccine Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "7.79%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-6.11%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.09",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "3.97%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "11961449374.10",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1202682148.07",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "3.18%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "15.56%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "70.92%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "7.79%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-6.11%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-8.11%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-5.06%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "245.74%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "7.79%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.17",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "16.05%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 60.81 | 26/81 | 175.88 | 64.33 | 51.96 |
| PB | 1.99 | 25/81 | 2.22 | 2.02 | 1.75 |
| PS (TTM) | 9.46 | 45/81 | 12.69 | 10.14 | 9.17 |
| Dividend Yield | 4.17% | 4/81 | 4.06% | 3.58% | 1.13% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | Biocytogen (688796.SH) | A | A | E | B | A | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-11T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 18.97 |
| Highest Target | 30.00 |
| Lowest Target | 23.68 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/301207.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/301207.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/301207.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/301207.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**